Announcements Trials
Browse Landscape

Status

Recruiting 301Completed 286Terminated 146Active not recruiting 136Unknown 122Not yet recruiting 84Withdrawn 50Suspended 10No longer available 4Enrolling by invitation 4Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 4Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Metastatic gpNMB Expressing Triple Negative Breast Cancer 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Brain Neoplasms 1Advanced Breast Cancer (Female) 1

Interventions

veliparib 2leronlimab 1iniparib 1Vinorelbine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × Triple Negative Breast Neoplasms × Breast × Clear all
NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.

No longer available
Breast

Triple Negative Breast Neoplasms

NCT03123211 2022-05-24

Expanded Access to Veliparib

AbbVie

No longer available
Breast

Triple Negative Breast Neoplasms

NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

University of Washington

No longer available
Breast

Triple Negative Breast Neoplasms

NCT01130259 2013-09-17

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Sanofi

No longer available
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡